Introduction
GG-CSF-mobilized PBPCs have become the most widely used source of hematopoietic progenitor cells (HPCs) for transplantation procedures, and their mobilization is clinically safe. G-CSF is used to mobilize PBPCs in patients with malignancies, as well as in healthy donors for autologous and allogeneic PBPC transplantation. [1] [2] [3] It reduces the aplasia period and hence fever and infections during transplantation. 4 However, the use of G-CSF after autologous PBPC transplantation has been queried, as its further reduction in time to a safe neutrophil count 5, 6 does not always imply fewer significant clinical events, such as infections, length of hospitalization, extrahematological toxicities or mortality. 7, 8 Even so, the ASCO guidelines still recommend the use of growth factors after autologous PBPC transplantation. 9 G-CSF induces the proliferation and differentiation of myeloid precursor cells, and also provides a functional activity that influences chemotaxis, respiratory burst and Ag expression of neutrophils. Comparison of HPCmobilizing regimens is greatly impeded by the considerable variability of their responses. The two G-CSF recombinant preparations (lenograstim and filgrastim) currently available for HPC mobilization are produced in different ways. Lenograstim is obtained from Chinese hamster ovarian cells, and consists of 174 amino acids with 4% glycosylation. 10 Filgrastim is produced using Escherichia coli, has a methionine group at its N-terminal end and is not glycosylated.
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In this study, we compared the HSC-mobilizing efficacy of glycosylated vs non-glycosylated G-CSF in terms of the number of CD34 þ cells collected and the number of leukaphereses needed to reach their collection target. Secondary end points were the following: days to recover WBC and plts, and assessment of toxicity and percentage of patients who achieved the collection target in a single course of mobilization (high-dose CY plus G-CSF plus three leukaphereses).
Patients and methods

Patients
A total of 86 patients (48 men and 38 women, Table 1 ) who underwent auto-SCT for multiple myeloma (MM: 44 patients), non-Hodgkin's lymphoma (NHL: 31 patients) or Hodgkin's lymphoma (HL: 11 patients) between 2000 and 2008 were consecutively included in this controlled, non-randomized study.
Inclusion criteria were the same as those for auto-SCT: age o70 years, serum creatinine o200 mmol/l, cardiac ejection fraction 450%, DLCO (diffusing capacity of the lung for carbon monoxide) 450% and no active infection or other disease causing comorbidity. 12 Overall 55 patients (29 men and 26 women; median age 53.7 years, range 36-64) were enrolled in Arm A and 31 patients (19 males and 12 females; median age 49.5 years, range 34-60) were enrolled in arm B. At mobilization, 11 patients had achieved CR, 58 had achieved PR, 11 had stable disease and 6 had disease progression. This was a single-center prospective study in which patients were assigned 1.5:1 to the two arms, paying attention to their characteristics to equilibrate the arms. Also the patient groups were well equilibrated for factors that could affect mobilization, such as number of earlier chemotherapy, radiation therapy and BM involvement.
The study was approved by the Local Ethical Committee, and all patients gave their informed consent according to the Declaration of Helsinki Principles.
Treatment program
All patients received only induction therapy with dexamethasone, adriamycin, vincristin (DAV) Â 4 courses (MM patients), CHOP Â 6 courses (NHL patients) or ABVD Â 6 courses (HL patients). The transplant indication in NHL and HL patients was related to high-risk disease: International Prognostic Index (IPI) 2-4 or refractory disease in NHL, refractory disease in HL. The mobilization regimen was administered after 45 ± 5 days after the end of induction therapy. In MM patients, it consisted of CY 3 or 4 g/m 2 at day 0, on the basis of disease status at mobilization and performance status; in patients with lymphomas, it was 7 g/m 2 at day 0. Thereafter, patients received 10 mg/kg/day s.c. of glycosylated Hu G-CSF (Arm A) or non-glycosylated rHu G-CSF (Arm B) on days 1-12. From day 12, patients were apheresed for 2 days and the CD34 þ cell content was evaluated by FACS analysis. If the patient did not reach the minimum CD34 þ cells target, a third apheresis was performed. The apheresis mean volume after plasma detraction was 84±14 ml in Arm A and 87±16 ml in Arm B. If the minimum HPC target (X3 Â 10 6 /CD34 þ cells/kg body weight (b.w.)) was not reached after three apheretic procedures, patients were re-mobilized after at least 1 month.
Toxicity
All adverse events were considered during the mobilization period (days 0-15). The days to WBC and plt recovery were those from the day of high-dose CY administration (day 0) to the day of counts recovery.
Statistical analysis
Data were analyzed with the SPSS (Chicago, IL, USA) software package. All results are presented as median ± 1 s.d. (range). The medians were compared with the MannWhitney U-test. P values o0.005 were considered significant. One-way ANOVA analysis was used to compare all parameters between patients with MM, NLH and HL, also with respect to CY doses, earlier therapy and BM involvement.
Results
Results of mobilization and leukapheresis
A significantly higher CD34 þ collection was obtained from patients in Arm A (glycosylated Hu G-CSF) than from patients in Arm B (non-glycosylated rHu G-CSF): 15.34 ± 3.1 Â 10 6 CD34 þ cells/kg b.w. vs 11.04 ± 2.41 Â 10 6 CD34 þ /kg b.w., respectively (Po0.01) (Figure 1a ), and the percentage of patients who reached the minimum collection target after two leukaphereses was higher in those treated with glycosylated G-CSF (75 vs 48%, respectively, Po0.001). The apheresis' mean volume after plasma detraction was 54 ± 14 ml in Arm A and 57 ± 16 ml in Arm B. These results show that glycosylated G-CSF provided more adequate mobilization and accelerated the target collection time, indicating that it mobilizes BM HSCs more effectively and in greater numbers. No differences were observed between the MM, NLH or HL groups, nor with regard to the different CY doses 
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Adverse events
Toxicity associated with the two regimens was similar in terms of bone pain, fatigue, fever, mucositis and infections ( Table 2 ). All infections were controlled with antibiotics and resolved after WBC recovery. Finally, no differences within groups were observed in terms of days to WBC recovery to X500 and X1000/mm 3 ( Figure 1b ) and plts to X50 000/mm 3 ( Figure 1c) . No plt transfusions were needed.
Discussion
Several studies have shown that the response to high-dose chemotherapy and auto-SCT influences survival, especially when responders are compared with nonresponders. 13, 14 In 1988, G-CSF was found to mobilize HPCs into the bloodstream, and this effect was even greater when it was administered after myelosuppressive chemotherapy. 15 As a result, chemotherapy is no longer used alone as a mobilizing agent, but in combination with a hematopoietic cytokine, usually G-CSF. 16 Mobilization of HPCs in patients with malignancies is a routine practice in highdose therapy and auto-SCT. 17 The factors predicting the magnitude of HPC mobilization have been well documented. [18] [19] [20] The mobilizing regimen usually consists of CY of 3-7 g/m 2 or disease-specific agents. This study looked for differences in HPC mobilization in response to glycosylated Hu or nonglycosylated rHu G-CSF in patients with hematological tumors that are the most frequent candidates for auto-SCT and that require combined mobilization with chemotherapy and G-CSF. The appropriate schedule of mobilization in terms of type of chemotherapy, doses and timing of G-CSF administration has been discussed in several studies, 3, 18, [21] [22] [23] [24] [25] [26] whereas the role of G-CSF glycosylation is still not well defined.
Our primary objective was to determine whether nonglycosylated G-CSF (filgrastim) or glycosylated G-CSF (lenograstim) was more suitable for HPC mobilization. Glycosylation impacts G-CSF's pharmacokinetics. It is cleared through different pathways: a non-saturable mechanism in spleen and kidney, and a saturable mechanism in neutrophils. [27] [28] [29] Other studies have shown that G-CSF is degraded by serum enzymes, particularly elastases. Carter et al. 30 showed that glycosylation reduces this elastase-dependent inactivation. It may thus prolong G-CSF's activity and make it more effective. It has also been suggested that matrix metalloprotease-9 has a role in HPC mobilization as its serum levels increase on days 4 and 5 after G-CSF administration. 31 Perhaps, matrix metalloprotease-9 facilitates cell mobilization by degrading SDF-1, upregulating the CXCR4 expression of the CD34 þ cells and increasing their migration ability. 32 Moreover, there is experimental evidence that the quantity of sugars linked to proteins (glycosylation rate is 4% of its MW) is important in determining neutrophil activities. Neutrophils mobilized by lenograstim (glycosylated G-CSF) display a higher expression of the maturity markers 33 involved in recognition, adhesion, phagocytosis and interaction with Igs. The underlying mechanism for these greater effects remains elusive. The functions of neutrophils are modified by G-CSF, probably on account of the functional immaturity of mobilized cells occasioned by their accelerated release into the blood. This lower function may be responsible for the reduction of neutrophils after mobilization, and hence, less efficacy in reducing infections. The clinical significance of these observations remains to be elucidated by larger clinical studies evaluating the relationship between modified functional activity of in vivo-primed neutrophils and clinical outcome.
In healthy donors, 24 a significant difference was observed in the number of CD34 þ cells mobilized by glycosylated and non-glycosylated G-CSF. 31 In male donors mobilized with lenograstim on the morning of the first apheresis, circulating CD34 þ cells were marginally higher than in Table 2 Adverse events
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Treated with filgrastim those receiving filgrastim, but this difference was not confirmed in the CD34 þ collection. In contrast, Martino et al. 34 did not find any difference in healthy donors mobilized with glycosylated and non-glycosylated G-CSF.
No clear data have been obtained in patients who underwent auto-SCT and who received chemotherapy plus G-CSF during mobilization. Lefre`re et al. 35 did not find any difference between glycosylated and non-glycosylated G-CSF in 126 patients with hematological malignancies who underwent PBSC mobilization for auto-SCT. Also, Kopf et al. 36 did not find any difference in CD34 þ cell mobilization between patients receiving lenograstim, filgrastim or molgramostim. However, this study prevalently enrolled patients with solid tumors: in fact, it included only 14 NHL, 5 HL and 2 MM patients, of whom 2 HL and 1 NHL failed to mobilize. Also, the mobilizing therapy by Kopf et al. was very different from ours, and the G-CSF dose was lower than 5 mg/kg/day, hence much lower dose than the 10 mg/kg/day was used here. Moreover, the timing of the CD34 þ collection and the minimum target of collected CD34 þ cells differed from those used here: aphereses were performed when circulating CD34 þ cells were X20/ml, whereas we performed them at day 12; CD34 þ cells were X2 Â 10 6 /kg, whereas they were X3 Â 10 6 /kg in our study. The lack of differences between lenograstim and filgrastim in the Kopf et al. study may be thus explained by the different study design and patients' features. Despite these differences, Kopf et al. evidenced a more rapid mobilization in patients receiving lenograstim (day median number ¼ 12) than in those receiving filgrastim (day median number ¼ 13), which is in line with our results. The randomized study by Ataergin et al. 37 on patients with solid and hematological tumors agrees with our results, as it indicates that a lower dose of glycosylated G-CSF is as effective as the standard dose of non-glycosylated G-CSF for PBPC mobilization in patients undergoing auto-SCT.
Our results show that CY in association with glycosylated Hu G-CSF results in more adequate mobilization, and the HSC collection target is reached more quickly and requires fewer leukaphereses. The patients studied here were affected by MM, NHL or HL, hence they were typical candidates for auto-SCT and for combined mobilization with chemotherapy and G-CSF. Patients' parameters were well balanced between Arm A (glycosylated Hu G-CSF) and Arm B (non-glycosylated rHu G-CSF), and there were no between-group differences that could affect the PBPC yield. The higher efficacy of glycosylated Hu G-CSF was not influenced by the disease: no significant differences in terms of collected CD34 þ cells and percentage of patients achieving the target with two aphereses were shown between MM, LNH or LH patients, nor between patients treated with 3, 4 or 7 g/m 2 of CY. Patients with BM involvement at diagnosis achieved adequate collection with two apheresis sessions similar to patients with no BM involvement. Radiotherapy, which was performed in 11 patients (three MM, five NHL and three HL patients), did not affect the cell yield.
Our report suffers from some limitations. The number of HL patients was not sufficient to determine any difference between the two G-CSF types in the disease. Also patient accrual by a single institution cannot allow a phase III randomized study. However, center-to-center variations in the auto-SCT procedures prevented us in planning a multicenter phase III trial. Our study considered three types of hematological malignancies, but this was needed to reach a sufficiently large population to be examined. We did not monitor serum G-CSF levels or other parameters related to the mobilization process, which could possibly show some clues with regard to the lack of between-group differences. Parameters of this type, however, may be studied in a prospective randomized manner. The results obtained here may be regarded as a preliminary one: larger randomized trials are needed to confirm this conclusion and delineate the still unrevealed process of HPC mobilization by G-CSF after chemotherapy in patients with malignancies.
